Central Laboratory, The Affiliated Hospital of Yanbian University, Yanji, 133000, China.
Key Laboratory of Pathobiology (Yanbian University), State Ethnic Affairs Commission, Yanji, 133000, China.
Mol Biol Rep. 2023 Oct;50(10):8097-8109. doi: 10.1007/s11033-023-08675-z. Epub 2023 Aug 5.
Ferritin light chain (FTL) is involved in tumor progression, but the specific molecular processes by which FTL affects the development of breast cancer (BRCA) have remained unknown. In this research, the clinicopathological significance of FTL overexpression in BRCA was investigated.
To investigate the role of FTL in BRCA, we utilized multiple online databases to analyse FTL expression levels in BRCA. Next, we reviewed the expression and localization of the FTL protein in BRCA by immunohistochemistry (IHC), Western blot (WB) and immunofluorescence (IF) staining. To assess the impact of FTL on patient prognosis, we conducted Kaplan‒Meier, univariate and multivariate survival analyses. The relationship between FTL and immune infiltration in BRCA was also analysed in the TISCH and SangerBox databases. MTT, malondialdehyde (MDA) and reactive oxygen species (ROS) assays were carried out to investigate the molecular mechanisms of FTL action in BRCA cells.
FTL was significantly upregulated in BRCA compared to normal tissues. Its expression significantly linked to histological grade (P = 0.038), PR expression (P = 0.021), Her2 expression (P = 0.012) and Ki-67 expression (P = 0.040) in patients with BRCA. Furthermore, the expression of the FTL protein was higher in the BRCA cell lines than in the normal breast cells and mainly localized in the cytoplasm. Compared to patients with a low level of FTL expression, patients with a high level of FTL expression showed lower overall survival (OS). More convincingly, univariate and multivariate statistical analyses revealed that FTL expression (P = 0.000), ER expression (P = 0.036) and Her2 expression (P = 0.028) were meaningful independent prognostic factors in patients with BRCA. FTL was associated with immune infiltration in BRCA. Functional experiments further revealed that FTL knockdown inhibited the capacity of proliferation and increased the level of oxidative stress in BRCA cells.
Overexpression of FTL was associated with the progression of BRCA. FTL overexpression may become a biomarker for the evaluation of poor prognosis in patients with BRCA.
铁蛋白轻链(FTL)参与肿瘤进展,但 FTL 影响乳腺癌(BRCA)发展的确切分子过程尚不清楚。在这项研究中,研究了 FTL 在 BRCA 中过表达的临床病理意义。
为了研究 FTL 在 BRCA 中的作用,我们利用多个在线数据库分析了 BRCA 中 FTL 的表达水平。接下来,我们通过免疫组织化学(IHC)、Western blot(WB)和免疫荧光(IF)染色来研究 FTL 蛋白在 BRCA 中的表达和定位。为了评估 FTL 对患者预后的影响,我们进行了 Kaplan-Meier、单变量和多变量生存分析。还在 TISCH 和 SangerBox 数据库中分析了 FTL 与 BRCA 中免疫浸润的关系。进行 MTT、丙二醛(MDA)和活性氧(ROS)测定,以研究 FTL 在 BRCA 细胞中的作用的分子机制。
与正常组织相比,FTL 在 BRCA 中显著上调。其表达与组织学分级(P=0.038)、PR 表达(P=0.021)、Her2 表达(P=0.012)和 Ki-67 表达(P=0.040)显著相关。此外,FTL 蛋白的表达在 BRCA 细胞系中高于正常乳腺细胞,主要定位于细胞质中。与 FTL 低表达的患者相比,FTL 高表达的患者总生存率(OS)较低。更有说服力的是,单变量和多变量统计分析表明,FTL 表达(P=0.000)、ER 表达(P=0.036)和 Her2 表达(P=0.028)是 BRCA 患者有意义的独立预后因素。FTL 与 BRCA 中的免疫浸润有关。功能实验进一步表明,FTL 敲低抑制了 BRCA 细胞的增殖能力,并增加了氧化应激水平。
FTL 的过表达与 BRCA 的进展有关。FTL 过表达可能成为评估 BRCA 患者预后不良的生物标志物。